Patents by Inventor Charles Mackay
Charles Mackay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9567398Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: GrantFiled: November 17, 2011Date of Patent: February 14, 2017Assignee: MERCK SERONO S.A.Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
-
Patent number: 9567397Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: GrantFiled: November 17, 2011Date of Patent: February 14, 2017Assignee: MERCK SERONO S.A.Inventors: Laurent Magnenat, Olivier Leger, Charles Mackay, David Georges Zahra
-
Publication number: 20140065163Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: ApplicationFiled: November 17, 2011Publication date: March 6, 2014Inventors: Laurent Magnenat, Olivier Leger, Charles MacKay, David Georges Zahra
-
Publication number: 20140023641Abstract: The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases.Type: ApplicationFiled: November 17, 2011Publication date: January 23, 2014Applicant: Merck Serono S.A.Inventors: Laurent Magnenant, Olivier Leger, Charles Mackay, David Georges Zahra
-
Publication number: 20120315275Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: ApplicationFiled: August 20, 2012Publication date: December 13, 2012Inventors: Peter Whitefeld, David Zahra, Charles Mackay
-
Patent number: 8268972Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: February 19, 2009Date of Patent: September 18, 2012Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Mackay
-
Patent number: 8236933Abstract: The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease/disorder of bone tissue.Type: GrantFiled: April 13, 2006Date of Patent: August 7, 2012Assignee: Garvan Institute of Medical ResearchInventors: Herbert Herzog, Charles Mackay
-
Publication number: 20110190477Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: ApplicationFiled: February 19, 2009Publication date: August 4, 2011Inventors: Peter Whitfeld, David Zahra, Charles Mackay
-
Publication number: 20110044996Abstract: The present invention provides antibodies that bind, interact or otherwise associate with GM-CSF or a fragment, portion or part thereof and antagonize or neutralize GM-CSF activity. In accordance with embodiments of the present invention humanized monoclonal antibodies are generated which bind to human GM-CSF with high affinity and which inhibit the activity of GM-CSF.Type: ApplicationFiled: May 23, 2008Publication date: February 24, 2011Inventors: Charles Mackay, David Zahra
-
Patent number: 7858326Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: August 1, 2008Date of Patent: December 28, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20100297135Abstract: Provided herein are immunogenic peptides of GM-CSF comprising an amino acid sequence set forth in any one of SEQ ID NOs:2 to 6, or a portion thereof, and compounds and molecules that specifically interact with or bind to a region of GM-CSF located between, or corresponding to a region located between, about residues 89 and 117 of the human GM-CSF polypeptide sequence as set forth in SEQ NO:1.Type: ApplicationFiled: November 12, 2008Publication date: November 25, 2010Applicant: CRC FOR ASTHMA AND AIRWAYS LTD.Inventors: Charles Mackay, David Zahra
-
Publication number: 20100143934Abstract: The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease/disorder of bone tissue.Type: ApplicationFiled: April 13, 2006Publication date: June 10, 2010Applicant: Garvan Institute of Medical ResearchInventors: Herbert Herzog, Charles Mackay
-
Publication number: 20090110659Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: ApplicationFiled: August 1, 2008Publication date: April 30, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20080254030Abstract: Compositions and methods for treating Th2-mediated disease are provided.Type: ApplicationFiled: January 27, 2006Publication date: October 16, 2008Inventors: Charles Mackay, Fabienne Mackay, Susan Kalled
-
Patent number: 7423129Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: September 13, 2007Date of Patent: September 9, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20080070300Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: ApplicationFiled: September 13, 2007Publication date: March 20, 2008Inventors: Paul Ponath, Shixin Qin, Douglas Ringler, Walter Newman, Charles Mackay
-
Publication number: 20070277252Abstract: The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals in methods of screening for agonists, inverse agonists and antagonists of human C5aR and for testing efficacy of C5aR agonists, inverse agonists and antagonists in various animal models of disease.Type: ApplicationFiled: December 24, 2004Publication date: November 29, 2007Inventor: Charles Mackay
-
Patent number: 7285620Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.Type: GrantFiled: May 19, 2005Date of Patent: October 23, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Patent number: 7265201Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to proteins or polypeptides referred to herein as isolated and/or recombinant human eotaxin, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, which are useful in in vitro methods, diagnostic and/or therapeutic applications. Also provided are methods of use of the proteins of the present invention, for example in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used in assays to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin function.Type: GrantFiled: June 23, 1995Date of Patent: September 4, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
-
Publication number: 20070054321Abstract: The present invention relates generally to the diagnosis and treatment of inflammatory diseases such as rheumatoid arthritis and asthma in humans and other animals. The invention also relates to a method for identifying agonists and antagonists of the enzyme PAC-1 (DUSP2) that are useful in the therapeutic methods described herein. The present invention relates generally to the diagnosis and treatment of inflammatory diseases such as rheumatoid arthritis and asthma in humans and other animals. The invention also relates to a method for identifying agonists and antagonists of the enzyme PAC-1 (DUSP2) that are useful in the therapeutic methods described herein.Type: ApplicationFiled: February 12, 2004Publication date: March 8, 2007Applicant: G2 THERAPIES LTD.Inventors: Kate Jeffrey, Charles Mackay, Michael Rolph